Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Pharmaxis’s Bronchitol found to be safe in Phase III bronchiectasis study
A total of 123 subjects started treatment with 320mg Bronchitol twice per day and 99 subjects completed the full 12 months of the trial. Of the 24 withdrawals,
A total of 123 subjects started treatment with 320mg Bronchitol twice per day and 99 subjects completed the full 12 months of the trial. Of the 24 withdrawals,
The new antibodies were announced as the latest additions to the Human Protein Atlas portal. Initially consisting of 1,800 antibodies, the portfolio has grown to over 3,800 antibodies
This agent is said to be the first product developed out of the Merck-VisEn Biomarker Imaging research collaboration announced in 2007, and will enable researchers to image and
Oral dnaJP1 is a once-daily epitope specific immunotherapy for rheumatoid arthritis (RA) patients. Oral dnaJP1 is a heat shock protein (hsp)-derived peptide which was previously identified as a
Covidien Ventures will be managed by Daniel Sheehan, vice president of Corporate Venture Capital, who recently joined Covidien from Affinity Capital Management. Mr Sheehan, who has 20 years
Owens & Minor will pay $30.2 million for the net assets of The Burrows Company and will assume the company’s debt. The final purchase price will be subject
The new biomarker, present in many common cancers, is a target of drugs being evaluated by Lixte and the National Institute of Neurological Disorders and Stroke (NINDS) for
According to the company, the small cationic peptides covered by the University of Michigan intellectual property are capable of forming stable siRNA nanoparticle complexes, thereby protecting the siRNA
The study is designed to evaluate the safety and efficacy of a novel non-dopaminergic approach for reestablishing motor function in Parkinson’s patients who are sub-optimally responsive to drug
The Karolinska Institute has completed a 38-subject Phase I trial testing a prime-boost HIV vaccine regimen using three doses of unadjuvanted DNA vaccines over a three-month period followed